D.A. Diagnostics (Stock Code: 300244), DragonNet Technology (Stock Code: 300245) and Biolight (Stock Code: 300246) will land on ChiNext board on July 19, 2011.

D.A. Diagnostics’ IPO volume is 12.80 million with the post-IPO share capital totaling 51.10 million, the offering price of 23.50 yuan per share, the raised funds expected up to 301.00 million yuan. DragonNet Technology’s IPO volume is 17.00 million with the post-IPO share capital totaling 67.00 million, the offering price of 20.00 yuan per share, the raised funds expected up to 340.00 million yuan. Biolight’s IPO volume is 10.50 million with the post-IPO share capital totaling 40.58 million, the offering price of 25.00 yuan per share, the raised funds expected up to 263.00 million yuan.

Zhejiang D.A. Diagnostics Co., Ltd. principally engages in the offering of agency service for the subcontracting of medical diagnosis services and the sales of vitro diagnosis products. In 2010, its operating income reached 343 million yuan with the net profit of about 29.9152 million yuan.

Shanghai DragonNet Technology Co., Ltd. principally engages in the offering of third-party services for the IT infrastructure composed of multi-brand products. In 2010, its operating income reached 169 million yuan with the net profit of about 43.6612 million yuan.

Guangdong Biolight Meditech Co., Ltd. principally engages in the research, development, manufacturing and sale of medical monitor and the relevant medical instruments. In 2010, its operating income reached 144 million yuan with the net profit of about 32.9913 million yuan.

Source:szse.cn